PE-22-28: The TREK-1 Channel Peptide Being Studied for Depression

AI generatednootropicemerging
This article was AI-generated for informational purposes only. It is not medical advice. Always verify claims with the cited sources.

Most of the peptides in this research log come from metabolism, healing, or growth-factor biology. PE-22-28 is different: it comes from mood research, and specifically from a single, unusual drug target — the TREK-1 potassium channel. It is one of the more mechanistically interesting entries in the PepStash library, and also one of the easiest to overstate. So let's keep the framing tight from the start: everything credible we know about PE-22-28 comes from rodents, from essentially one research group, and none of it has been tested in a human being.

Where it comes from: spadin and the sortilin propeptide

To understand PE-22-28 you have to start with spadin. Spadin is a naturally occurring 17-residue peptide cleaved from the sortilin propeptide (also called NTSR3). It was identified by Mazella and colleagues in a 2010 PLoS Biology paper as a selective blocker of the TREK-1 channel that produced antidepressant-like behavior in mice.

Spadin had a problem, though: it was short-lived and relatively weak. So the same lineage of researchers went looking for a smaller, sturdier fragment. PE-22-28 is the result — a synthetic 7-residue peptide spanning residues 22 through 28 of spadin. The lead publication is Djillani et al., 2017, in Frontiers in Pharmacology, titled "Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity." That title is basically the whole thesis: take spadin, shorten it, and you get something that binds harder and lasts longer.

The mechanism: blocking a "leak" channel

TREK-1 (TWIK-related potassium channel 1) is a two-pore-domain potassium channel. Its normal job is to let potassium leak out of neurons, which nudges them toward a quieter, less-excitable state. It is expressed in mood- and cognition-relevant regions like the hippocampus and cortex.

The proposed logic is straightforward: TREK-1 activity has been linked to a depressive-like state, and knocking out the channel in mice produces a "depression-resistant" phenotype. If you block that leak pharmacologically, certain neurons — including serotonin-producing ones — become easier to fire. PE-22-28 is a TREK-1 blocker, so the antidepressant hypothesis is that inhibiting the channel shifts this balance. That is a clean, testable mechanism, and it is genuinely different from how SSRIs work. It is also still a hypothesis built on animal data.

What the rodent data actually showed

The Djillani 2017 work reported a few specific findings, all in male C57Bl/6J mice:

  • Higher binding potency. PE-22-28 was reported with an IC50 around 0.12 nM at TREK-1, versus roughly 40–60 nM for spadin — an over-300-fold improvement in blocking potency on paper.
  • Longer duration of action. The functional action duration was extended to about 23 hours, compared with roughly 7 hours for spadin.
  • Behavioral effects. Across three standard rodent depression paradigms — the forced swim test, novelty-suppressed feeding, and learned helplessness — the analogs reduced despair-type behaviors.
  • Rapid neurogenesis. The peptides were reported to induce hippocampal neurogenesis after only a 4-day treatment, which the authors contrasted with the multi-week onset typical of conventional antidepressants.

    • The "fast-acting" angle — measurable effects in days rather than weeks — is the single most repeated claim about PE-22-28 online. It is worth noting where it comes from: a behavioral and histology readout in mice, not a mood-rating scale in people.

    The skeptical read

    Here is where a research log has to slow the hype down.

    It is strictly preclinical. There are no human clinical trials of PE-22-28. Not a completed one, not an ongoing one that we can point to. Everything above is rodent behavior and channel pharmacology.

    The evidence base is narrow. The core findings trace back to essentially one research group and a small cluster of publications. That is normal for an early-stage compound, but it means the results have not been broadly, independently replicated. Impressive nanomolar IC50 numbers and fast neurogenesis are exactly the kind of results that need outside confirmation before anyone leans on them.

    Behavioral tests are not depression. The forced swim and learned helplessness assays are screening tools. Plenty of compounds that "work" in these tests never translate to human benefit. Predictive validity here is real but limited.

    Safety is essentially unknown. Beyond basic tolerability in mice, there is no human safety, dosing, or long-term data. A drug target this central to neuronal excitability deserves particular caution.

    Regulatory status: PE-22-28 is not an approved drug and is not an approved treatment for depression or anything else. It is a research compound. You can check how we track this on the FDA status page, and the short version is that it sits firmly in the research-only bucket.

    Why it's still worth logging

    Despite all the caveats, PE-22-28 is a legitimately interesting scientific story: a naturally derived peptide, a novel ion-channel target that sidesteps the monoamine pathway most antidepressants use, and a fast-onset signal in animals. That combination is why it keeps showing up in peptide discussions. It is a good example of an idea that is exciting at the bench and completely unproven in the clinic — and both of those things can be true at once.

    If you want the structured data view — sequence, target, and status flags — see the PE-22-28 library entry.

    PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.

    Not medical advice. For research purposes only. Consult a licensed physician before beginning any protocol.